메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for indivi
- 김갑성 기자
- 2025-08-05 18:40
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors

DONGGUAN, China, Aug 5, 2025 -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital. The patient has completed the Dose Limiting Toxicity (DLT) observation period with a favorable safety profile. The trial aims to evaluate the safety and tolerability of FP008 in patients with advanced solid tumors. As the latest next generation of immuno-oncology (IO) app
- 김갑성 기자
- 2025-08-05 16:30
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion

GUANGZHOU, China, Aug. 5, 2025 -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange on August 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwide sales network resources of Sunshine Lake Pharma Co., Ltd. This forms an R&D-manufacturing-sales closed loop to accelerate global operations, thereby driving value reshaping and laying a more solid foundation for future sustainable development, including international expansion. This year, propell
- 김갑성 기자
- 2025-08-05 15:34
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation

BANGKOK, Aug. 4, 2025 -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. in Japan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the company's exceptional efforts in driving community impact and environmental sustainability through healthcare-focused innovation and compassion. In the Social Empowerment category, CPT was recognized for its heartfelt and impactful charitable initiatives. Through its annual charity cycling event, CPT not only
- 김갑성 기자
- 2025-08-05 13:02
TSH Biopharm Honored for Social Empowerment and Green Leadership at the Asia Responsible Enterprise Awards 2025

BANGKOK, Aug. 4, 2025 -- TSH Biopharm Corporation Ltd. has been recognized with dual honors at the Asia Responsible Enterprise Awards 2025, receiving accolades for the Green Leadership and Social Empowerment categories. The awards reflect the company's growing influence as a purpose-driven pharmaceutical firm that integrates sustainability and human well-being into its corporate DNA. TSH Biopharm's Green Leadership accolade celebrates its signature initiative, "Sowing with Heart," which redefines the connection between health and the environment. In a pioneering effort, the c
- 김갑성 기자
- 2025-08-05 12:27
WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity

WUXI, China, Aug. 5, 2025 -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has completed GMP release at the end of July, signifying the company's relentless pursuit of excellence in capacity expansion and business growth. In just 18 months, WuXi XDC has rapidly completed the advanced design, construction, equipment qualification, media fill and GMP release of the DP3
- 김갑성 기자
- 2025-08-05 10:13
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Takes Global Stage

BANGKOK, Aug. 5, 2025 -- Chulalongkorn University's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva, along with a special award from Malaysia. Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is prepar
- 김갑성 기자
- 2025-08-05 10:00
METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing's Biopharmaceutical Innovation Engine

BEIJING, China, Aug. 5, 2025 -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series D financing round. The announcement was made at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, a key hub for Beijing's life sciences sector. Financing Co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund The Series D round was co-led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund
- 황정호 기자
- 2025-08-05 08:08
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule
- 김갑성 기자
- 2025-08-05 08:00
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS 'BURN LINES' SOCIAL MEDIA TREND

PARIS, Aug. 5, 2025 -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked widespread concern among global health experts. France's Minister of Health stated recently: "For a few seconds of buzz on social media, young people are destroying their skin cells for life. We only get one skin." LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITME
- 김갑성 기자
- 2025-08-05 05:15

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-08-31_SUN

마이디어 그룹, 2025년 상반기 사상 최고 실적 달성 03:54

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 05시 20분